Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axcella Health Inc.AXLA · Entity 116059 | Director | May 20, 2021 | May 24, 2021 |
| Moderna, Inc.MRNA · Entity 2025 | President | September 14, 2026 | September 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axcella Health Inc.
Report date May 20, 2021 · Filed May 24, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.24 · Expires 2031-05-19 | Direct | 20,000 |
Reported balance
After 2021-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-20 · Grant · Acquired 20,000 · Balance 20,000 F1: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting.
Moderna, Inc.
Report date September 14, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,562,029 |
Ending reported balance
After 2026-09-15 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-09-14 · Exercise / conversion · Acquired 76,453 · Balance 1,566,152 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. Row 2 · 2026-09-14 · Sale · Disposed 40,294 · Balance 1,525,858 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.99 to $144.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Row 3 · 2026-09-15 · Exercise / conversion · Acquired 76,452 · Balance 1,602,310 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. Row 4 · 2026-09-15 · Sale · Disposed 40,281 · Balance 1,562,029 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $145.97 to $146.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.21 · Expires 2027-02-23 | Direct | 382,262 |
Reported balance
After 2026-09-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-14 · Exercise / conversion · Disposed 76,453 · Balance 382,262 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F5: This option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.21 · Expires 2027-02-23 | Direct | 305,810 |
Reported balance
After 2026-09-15 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-15 · Exercise / conversion · Disposed 76,452 · Balance 305,810 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F5: This option is fully vested and exercisable. |
| Common StockSEC Table I · non-derivative | IndirectBy Valhalla, LLC | 4,116 |
Reported balance
Holding disclosure · report date 2026-09-14 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 4,116 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 151,933 |
Reported balance
Holding disclosure · report date 2026-09-14 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 151,933 F4: These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.99 to $144.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $145.97 to $146.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4: These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F5: This option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 16, 2026 20:48 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 76,452 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001682852-26-000176 · form4.xml · derivative · entry 8 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 305,810 Underlying: Common Stock · 76,452 shares Expires 2027-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F5 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| September 15, 2026 Filed Sep 16, 2026 20:48 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 40,281 | $146.07 | $5,883,845.67 |
DisclosureSEC source: 0001682852-26-000176 · form4.xml · nonDerivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,562,029 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $145.97 to $146.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 15, 2026 Filed Sep 16, 2026 20:48 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 76,452 | $12.21 | $933,478.92 |
DisclosureSEC source: 0001682852-26-000176 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,602,310 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. Read SEC document |
| September 14, 2026 Filed Sep 16, 2026 20:48 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 76,453 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001682852-26-000176 · form4.xml · derivative · entry 7 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 382,262 Underlying: Common Stock · 76,453 shares Expires 2027-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F5 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| September 14, 2026 Filed Sep 16, 2026 20:48 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 40,294 | $144.13 | $5,807,574.22 |
DisclosureSEC source: 0001682852-26-000176 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,525,858 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.99 to $144.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 14, 2026 Filed Sep 16, 2026 20:48 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 76,453 | $12.21 | $933,491.13 |
DisclosureSEC source: 0001682852-26-000176 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,566,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:50 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 9,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000163 · form4.xml · derivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,828 Underlying: Common Stock · 9,283 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:50 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 4,489 | $140.34 | $629,986.26 |
DisclosureSEC source: 0001682852-26-000163 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,489,699 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:50 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 9,283 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000163 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,494,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 28, 2026 Filed Aug 31, 2026 20:51 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 611 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000161 · form4.xml · derivative · entry 8 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,221 Underlying: Common Stock · 611 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F5 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| August 28, 2026 Filed Aug 31, 2026 20:51 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 296 | $142.77 | $42,259.92 |
DisclosureSEC source: 0001682852-26-000161 · form4.xml · nonDerivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,484,905 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| August 28, 2026 Filed Aug 31, 2026 20:51 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 611 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000161 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,485,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 27, 2026 Filed Aug 31, 2026 20:51 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000161 · form4.xml · derivative · entry 7 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,621 Underlying: Common Stock · 1,437 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| August 27, 2026 Filed Aug 31, 2026 20:51 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 695 | $149.66 | $104,013.70 |
DisclosureSEC source: 0001682852-26-000161 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,484,590 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| August 27, 2026 Filed Aug 31, 2026 20:51 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,437 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000161 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,485,285 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| July 15, 2026 Filed Jul 16, 2026 20:45 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,110 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001682852-26-000141 · form4.xml · derivative · entry 7 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,110 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| July 15, 2026 Filed Jul 16, 2026 20:45 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 37,226 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001682852-26-000141 · form4.xml · derivative · entry 6 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,226 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| July 15, 2026 Filed Jul 16, 2026 20:45 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 53,336 | $67.60 | $3,605,513.60 |
DisclosureSEC source: 0001682852-26-000141 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,483,848 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. Read SEC document |
| July 15, 2026 Filed Jul 16, 2026 20:45 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 16,110 | $19.15 | $308,506.50 |
DisclosureSEC source: 0001682852-26-000141 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,537,184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. Read SEC document |
| July 15, 2026 Filed Jul 16, 2026 20:45 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 37,226 | $19.15 | $712,877.90 |
DisclosureSEC source: 0001682852-26-000141 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,521,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,110 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001682852-26-000121 · form4.xml · derivative · entry 7 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,110 Underlying: Common Stock · 16,110 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 37,226 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001682852-26-000121 · form4.xml · derivative · entry 6 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,226 Underlying: Common Stock · 37,226 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:10 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 53,336 | $51.37 | $2,739,870.32 |
DisclosureSEC source: 0001682852-26-000121 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,483,848 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 16,110 | $19.15 | $308,506.50 |
DisclosureSEC source: 0001682852-26-000121 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,537,184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 37,226 | $19.15 | $712,877.90 |
DisclosureSEC source: 0001682852-26-000121 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,521,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 20:16 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 9,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000111 · form4.xml · derivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,111 Underlying: Common Stock · 9,282 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 20:16 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 4,488 | $47.19 | $211,788.72 |
DisclosureSEC source: 0001682852-26-000111 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,483,848 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 20:16 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 9,282 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000111 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,488,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 28, 2026 Filed May 29, 2026 21:04 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 610 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000105 · form4.xml · derivative · entry 8 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,832 Underlying: Common Stock · 610 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F5 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| May 28, 2026 Filed May 29, 2026 21:04 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 295 | $47.61 | $14,044.95 |
DisclosureSEC source: 0001682852-26-000105 · form4.xml · nonDerivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,479,054 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| May 28, 2026 Filed May 29, 2026 21:04 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 610 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000105 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,479,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 27, 2026 Filed May 29, 2026 21:04 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000105 · form4.xml · derivative · entry 7 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,058 Underlying: Common Stock · 1,437 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| May 27, 2026 Filed May 29, 2026 21:04 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 695 | $47.03 | $32,685.85 |
DisclosureSEC source: 0001682852-26-000105 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,478,739 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| May 27, 2026 Filed May 29, 2026 21:04 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,437 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000105 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,479,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:57 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,110 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001682852-26-000103 · form4.xml · derivative · entry 7 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,220 Underlying: Common Stock · 16,110 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:57 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 37,226 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001682852-26-000103 · form4.xml · derivative · entry 6 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,452 Underlying: Common Stock · 37,226 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:57 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 53,336 | $48.40 | $2,581,462.40 |
DisclosureSEC source: 0001682852-26-000103 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,477,997 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:57 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 16,110 | $19.15 | $308,506.50 |
DisclosureSEC source: 0001682852-26-000103 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,531,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:57 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 37,226 | $19.15 | $712,877.90 |
DisclosureSEC source: 0001682852-26-000103 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,515,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:14 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 165,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000042 · form4.xml · derivative · entry 16 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,230 Underlying: Common Stock · 165,230 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F9 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award will vest on March 1, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F9 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award will vest on March 1, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:14 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 125,466 | $0.00 Strike: $53.57 | $0.00 |
DisclosureSEC source: 0001682852-26-000042 · form4.xml · derivative · entry 15 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,466 Underlying: Common Stock · 125,466 shares Expires 2036-03-01 F8 · derivative.exercise_date: 25% of this option will vest and become exercisable on March 1, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:14 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 37,131 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000042 · form4.xml · derivative · entry 14 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,393 Underlying: Common Stock · 37,131 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F7 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F7 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:14 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,436 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000042 · form4.xml · derivative · entry 13 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,495 Underlying: Common Stock · 1,436 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F6 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F6 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:14 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 611 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000042 · form4.xml · derivative · entry 12 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,442 Underlying: Common Stock · 611 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F5 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:14 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 652 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000042 · form4.xml · derivative · entry 11 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 652 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:14 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 17,953 | $51.71 | $928,349.63 |
DisclosureSEC source: 0001682852-26-000042 · form4.xml · nonDerivative · entry 8 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,477,997 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:14 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 37,131 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000042 · form4.xml · nonDerivative · entry 7 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,495,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:14 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 695 | $51.71 | $35,938.45 |
DisclosureSEC source: 0001682852-26-000042 · form4.xml · nonDerivative · entry 6 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,458,819 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:14 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,436 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000042 · form4.xml · nonDerivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,459,514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:14 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 296 | $51.71 | $15,306.16 |
DisclosureSEC source: 0001682852-26-000042 · form4.xml · nonDerivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,458,078 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.